LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
30.32
-0.49 (-1.59%)
Oct 29, 2025, 1:13 PM EDT - Market open
Company Description
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.
LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021.
The company was founded in 2013 and is headquartered in Solana Beach, California.
LENZ Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Evert Schimmelpennink |
Contact Details
Address: 201 Lomas Santa Fe Drive, Suite 300 Solana Beach, California 92075 United States | |
| Phone | 858 925 7000 |
| Website | lenz-tx.com |
Stock Details
| Ticker Symbol | LENZ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001815776 |
| CUSIP Number | 52635N103 |
| ISIN Number | US52635N1037 |
| Employer ID | 84-4867570 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Evert B. Schimmelpennink | President, Chief Executive Officer, Secretary and Director |
| James W. McCollum | Co-Founder and Director |
| Daniel R. Chevallard CPA | Chief Financial Officer |
| Marc G. Odrich M.D. | Chief Medical Officer |
| Domenick Porfidia | Vice President of Sales |
| David Choromanski | Vice President of Marketing |
| Shawn Olsson | Chief Commercial Officer |
| Melissa Rosness | Senior Vice President of Manufacturing Operations |
| Kris Gambelin | Senior Vice President of Regulatory and Clincal Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 17, 2025 | SCHEDULE 13G | Filing |
| Oct 8, 2025 | 8-K | Current Report |
| Sep 30, 2025 | 8-K | Current Report |
| Sep 22, 2025 | SCHEDULE 13D/A | Filing |
| Aug 20, 2025 | SCHEDULE 13D/A | Filing |
| Jul 31, 2025 | 8-K | Current Report |
| Jul 30, 2025 | 10-Q | Quarterly Report |
| Jul 30, 2025 | 8-K | Current Report |
| Jul 14, 2025 | SCHEDULE 13D/A | Filing |
| Jun 24, 2025 | SCHEDULE 13D/A | Filing |